Technetium Tc 99M Nofetumomab Merpentan
Technetium Tc 99m nofetumomab merpentan is a radiolabeled murine monoclonal antibody fragment targeting a pancarcinoma antigen (NR-LU-10) expressed on epithelial tumors, used for immunoscintigraphic detection of small cell lung cancer and other carcinomas. The antibody fragment format improves tumor-to-background ratios compared to whole antibodies and reduces immunogenicity. It enables staging and restaging of carcinomas expressing the target antigen.
Mecanismo de Ação
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Technetium Tc 99m nofetumomab merpentan is a radiolabeled murine monoclonal antibody fragment targeting a pancarcinoma antigen (NR-LU-10) expressed on epithelial tumors, used for immunoscintigraphic detection of small cell lung cancer and other carcinomas. The antibody fragment format improves tumor-to-background ratios compared to whole antibodies and reduces immunogenicity. It enables staging and restaging of carcinomas expressing the target antigen.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Technetium Tc 99M Nofetumomab Merpentan is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109287. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="technetium-tc-99m-nofetumomab-merpentan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/technetium-tc-99m-nofetumomab-merpentan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/technetium-tc-99m-nofetumomab-merpentan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/technetium-tc-99m-nofetumomab-merpentan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="technetium-tc-99m-nofetumomab-merpentan"></drugfyi-drug>